Robarge, Jason D.
Desta, Zereunesay
Nguyen, Anne T.
Li, Lang
Hertz, Daniel
Rae, James M.
Hayes, Daniel F.
Storniolo, Anna M.
Stearns, Vered
Flockhart, David A.
Skaar, Todd C.
Henry, N. Lynn
Funding for this research was provided by:
National Institute of General Medical Sciences (U01 GM61373, 5T32 GM08425)
U.S. Department of Defense (W81XWH-10-1-0349)
Pfizer
Novartis
Article History
Received: 1 December 2016
Accepted: 2 December 2016
First Online: 9 December 2016
Compliance with ethical standards
:
: NLH received research funding from AstraZeneca, Eli Lilly, BioMarin Pharmaceuticals, Celldex Pharmaceuticals, and Sanofi Aventis. VS received research funding from Abbvie, Celgene, Medimmune, Merck, Novartis, Pfizer, and Puma. DFH worked as a consultant for Lilly Oncology, and received research funding from Merrimack, Lilly, Janssen R&D, Puma Biotechnology, Pfizer, and Astra Zeneca. DFH also has personal financial interest in Oncimmune and Inbiomotion and received royalties from Janssen R&D. DAF received research funding from Pfizer and Novartis and sat on the Scientific Board for Quest Diagnostics. The rest of the authors have no conflicts of interest to declare (JDR, ZD, ATN, LL, DLH, JMR, AMS, TCS).